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The terminology imposed by the
WAO reflects allergists’ poor understand-
ing of the extensive eczema/dermatitis
spectrum. The requirement for IgE testing
in their diagnostic scheme goes beyond
good clinical and scientific standards and
adds unnecessarily to health care costs.
That they were able to get a few
dermatologists to sign on is unfortunate,
especially now that the terminology has
crept into a scientific journal such as the
Journal of Investigative Dermatology. The
preceding comments are not meant to
detract from the efforts made by Schmitt,
Williams, and others to seek harmoniza-
tion of outcome measures for AD. It does
seem clear that we should, simulta-
neously, seek international agreement
on the terminology and definition of
AD. It is time to face these diversions
and seek global agreement on what is
best for our patients. Science cannot
proceed without internationally accepta-
ble definitions and logical terminology.
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TO THE EDITOR
In his comment on our paper recently
published in the Journal of Investiga-
tive Dermatology (Schmitt et al., 2011),
Dr Hanifin (2011) expresses concerns
that variants in the nomenclature may
impede the efforts of the international
community to harmonize outcome
measures for studies on atopic ecze-
ma/atopic dermatitis (Schmitt and
Williams, 2010).
Our call for a standardization of
outcome measures for atopic eczema
trials and for record keeping in clini-
cal practice resulted in considerable
interest and support from the interna-
tional research community and patient
groups throughout the world (Schmitt
et al., 2011). To harness such interest,
the Harmonising Outcome Measures for
Eczema (HOME) initiative (http://www.
homeforeczema.org) was founded in
July 2010 at the International Sympo-
sium on Atopic Dermatitis/New Trends
in Allergy meeting in Munich, Germany,
consisting of about 40 clinical researchers
and outcomes research methodologists
(Schmitt and Williams, 2010). At this
meeting, the majority of participants,
including Hanifin, expressed a clear
interest in proceeding further into
working on identifying core outcomes
for eczema research. A further HOME
meeting was held in Amsterdam in
June 2011, which also included indus-
try scientists and methodologists who
endorsed the core outcome domains
(i.e., the aspects of atopic eczema that
should be regularly measured in future
clinical trials) identified in the initial
international Delphi exercise (Schmitt
et al., 2011). This has led to a series
of projects to identify which mea-
sures are best suited for such domains.
The HOME initiative is also linked with
other international outcome measures
initiatives beyond the field of derma-
tology, such as COMET (Sinha et al.,
2008, 2009) and OMERACT (Tugwell
and Boers, 1993).
There are two main reasons why
we decided to call our initiative the
Harmonizing Outcomes Measures on
Eczema (HOME)-initiative. First, as
Hanifin correctly emphasizes, ‘‘eczema’’
is a term commonly used by patients
and by many physicians around the
world. As our initiative has a strong
focus on patients’ perspectives, it is a
necessary prerequisite for its success toAbbreviations: HOME, Harmonising Outcome Measures for Eczema; WAO, World Allergy Organization
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use terminology that is widely under-
stood. The second reason why we use
the term ‘‘eczema’’ relates to the inter-
national multidisciplinary focus of our
group. Even though it may be criticized
for the reasons pointed out by Hanifin,
‘‘eczema’’ is the term that the World
Allergy Organization (WAO) nomen-
clature committee, which included a
number of dermatologists, agreed on
(Johansson et al., 2004). The main
rationale for the revised nomenclature
was that the widespread use of the
term ‘‘atopic’’ in ‘‘atopic eczema’’ or
‘‘atopic dermatitis’’ was unscientific
because large population studies show
that anything from 20 to 100% of
such clinical phenotypes do not show
evidence of sensitization to environ-
mental allergens (Flohr et al., 2004).
There was no underlying agenda to
promote the possible role of IgE in
such a disease. Indeed, two of the
authors (CF and HW) have been among
the most vociferous critics of the pre-
occupation with the dubious etiological
role of atopy in eczema (Williams and
Flohr, 2006; Flohr et al., 2008). We
agree with Hanifin that people with the
clinical phenotype of eczema do not
need testing for IgE in order to make the
diagnosis; however, if that is the case,
it is not logical to call them ‘‘atopic’’,
a term that has a precise scientific
definition. It is also important to point
out that the WAO does not suggest
that the term ‘‘eczema’’ should be
applied loosely to all forms of eczema/
dermatitis such as nummular, venous,
or seborrheic, but just to the phenotype
of what Hanifin calls ‘‘atopic dermatitis’’.
The overarching structure of the WAO
classification starts with ‘‘dermatitis’’,
which is then subdivided into ‘‘eczema’’
(which can either be ‘‘atopic eczema’’
or ‘‘non-atopic’’ eczema, depending
on whether allergen testing has been
positive), ‘‘contact dermatitis’’ (which
can either be ‘‘irritant’’ or ‘‘allergic’’),
and other forms of dermatitis.
We are aware that much scientific
energy has gone into debating what to
call ‘‘non-atopic’’ eczema and terms
such as ‘‘intrinsic’’ or ‘‘atopiform’’ have
emerged without any clear agreement
or widespread adoption (Williams,
2000; Brenninkmeijer et al., 2008).
We agree with Hanifin in suggesting
that the role of atopy in eczema might
have been overemphasized in that it
adds little to our clinical predictive
ability, and it may well be the case
that other factors such as filaggrin skin
barrier gene mutation carriage may
become a better and more logical way
of dividing up eczema in the future
(Wuthrich and Schmid-Grendelmeier,
2003; Rodriguez et al., 2009). It is
for this reason that every consensus—
regardless of whether concerning core
outcome domains, nomenclature, or
diagnostic criteria—should be forever
preliminary and may be revised in the
future based on new knowledge.
The letter by Hanifin suggests that an
international consensus project concern-
ing the terminology of ‘‘atopic eczema’’/
‘‘atopic dermatitis’’ might be indicated.
This would clearly be a separate initia-
tive, independent from HOME, and
would need to include different stake-
holders (at least dermatologists, pedia-
tricians, and allergists); if Hanifin would
like to proceed from this discussion to an
international consensus initiative, we
would be very happy to participate.
We are delighted that Hanifin is
supporting the HOME initiative to
address the multiplicity of scales that
hampers current comparability of trials
of atopic eczema between countries
and over time and look forward to this
and other collaborative efforts to
strengthen evidence-based research
and improve medical care of patients
with (atopic) eczema.
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